Zobrazeno 1 - 10
of 321
pro vyhledávání: ''
Autor:
Mathias Witzens-Harig, Martin Soekler, Joerg Thomas Bittenbring, Lorenz Thurner, Andreas Viardot, Christian Berdel, Konstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Stephan Stilgenbauer, Gerhard Held, Philippe Jagoda, Ulrich Keller, Lorenz Truemper, Viola Poeschel, Vadim Lesan, Octavian Fleser, Moritz Bewarder
Publikováno v:
Leukemialymphoma. 63(2)
Patients with diffuse large B-cell lymphoma (DLBCL) treated with the R-CHOP regime receive a high cumulative dose of prednisone. We used computer tomography-ascertained Hounsfield units (HU) as a surrogate parameter for bone mineral density (BMD) in
Autor:
Teppei Obara, Jun Odawara, Yuju Ohno, Yasuo Mori, Goichi Yoshimoto, Toshihiro Miyamoto, Koichi Akashi, Ayano Yurino, Hiromi Iwasaki, Shuro Yoshida, Tetsuya Eto, Ryosuke Ogawa, Koji Kato, Toshiyuki Ueno, Takuro Kuriyama
Publikováno v:
Leukemialymphoma. 62(12)
We retrospectively analyzed 38 patients with AML who received azacitidine (AZA) to treat disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with objective response (OR) (n = 20) after AZA had significantly
Publikováno v:
Leukemialymphoma. 62(11)
The BOSTON trial showed that use of once-weekly selinexor, bortezomib, and dexamethasone (SVd) prolonged progression-free survival compared to twice-weekly bortezomib and dexamethasone (Vd) in patients with relapsed or refractory (R/R) multiple myelo
Publikováno v:
Leukemialymphoma. 62(10)
We aimed to compare real-world outcomes, resource use, and costs for patients with newly diagnosed multiple myeloma (NDMM) treated with continuous first-line (1 L) lenalidomide or fixed bortezomib in Europe. We performed a multicenter, retrospective,
Autor:
Adrian Minson, Michael Dickinson
Publikováno v:
Leukemialymphoma. 62(9)
High-grade transformation (HT) of follicular lymphoma (FL) to diffuse large B-cell lymphoma (DLBCL) is an infrequent yet highly clinically significant event, occurring in approximately 1–3% of pati...
Autor:
Kaiyang Ding, Xiao-Jun Liu, Bi-yun Chen, Qinhua Liu, Yu-Jun Dong, Juan Du, Wei Sang, Yongqiang Wei, Jing Liu, Jun Luo, Liang Zou, Juan He, Wei Wang, Wei Yang, Hongmei Jing, Jingsong He, Xinxin Cao, Zhongxing Jiang, Jian Li, Chunrui Li, Fei Li, Ou Bai, Rong Fu, Bingzong Li, Liang Wang, Zhen-Ling Li, Luoming Hua, Wenming Chen, Qi-ke Zhang, Yu Wu, Shuhua Yi, Chunyan Sun, Lugui Qiu, Lihong Liu, Xiao-Xia Chu, L. Wang, Min Mao
Publikováno v:
Leukemialymphoma. 62(11)
In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January 2003 and December 2019 at 35 tertiary hospitals in
Autor:
Ling Qin, Dayu Shi, Jian Huang, Hong-Xia Shi, Minghui Duan, Jihong Xu, Yanqiu Han, Xiaoli Liu, Chunting Zhao, Gusheng Tang, Meifang Wang, Xiequn Chen, Qian Jiang, Hongyan Tong, Limei Chen, Chunyan Chen, Xia Kuang, Wuhan Hui, Dongyun Li, Xin Du, Jianda Hu, Junling Zhuang, Ye Chen, Weihua Zhang, Wei Yang, Rong Liang, Zhijian Xiao, Zhuogang Liu, Wei Su
Publikováno v:
Leukemialymphoma. 62(11)
We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with mye
Autor:
Anne Pham-Ledard, Emilie Gérard, Pierre-Yves Dumas, Océane Ducharme, Laure Dequidt, Alyssa Benarfa, Marie Beylot-Barry
Publikováno v:
Leukemialymphoma. 62(10)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), formerly known as blastic natural killer cell lymphoma, is a rare and aggressive type of hematologic malignancy [1]. It belongs to the group of...
Autor:
Dieter Ayers, Shannon Cope, Faith E. Davies, Paula Rodriguez-Otero, Michel Delforge, Ali Mojebi, Kristen Hege, Katja Weisel, Jeroen P. Jansen, Sujith Dhanasiri
Publikováno v:
Leukemialymphoma. 62(10)
Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and a
Autor:
Louis M. Staudt, Amy S. Kimball, Sven de Vos, Jerry Ping, Darrin M. Beaupre, Wyndham H. Wilson, Da-Wei Huang, Kevin A. Kwei, George E. Wright, Leslie Popplewell, Jutta K. Neuenburg, Saurabh Chhabra, Tycel Phillips
Publikováno v:
Leukemialymphoma. 62(9)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in